Clinical Gastroenterology and Hepatology
Volume 7, Issue 10 , Page 1139, October 2009

Insufficient Evidence to Conclude Whether Anti–Tumor Necrosis Factor Therapy Increases the Risk of Lymphoma in Crohn's Disease

  • Laurent Peyrin–Biroulet, MD, PhD

      Affiliations

    • Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
    • ,
  • Jean–Frederic Colombel, MD

      Affiliations

    • Hopital Claude Huriez, Chu Lille, Lille, France
    • ,
  • William J. Sandborn, MD

      Affiliations

    • Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota

published online 25 May 2009.

Siegel et al1 reported an increased risk of lymphoma in Crohn's disease patients receiving combination therapy with anti–tumor necrosis factor (TNF) agents and immunomodulators. We believe that no definite conclusions can be drawn from this meta-analysis for the following reasons.

 

 Conflicts of interest The authors disclose no conflicts.

PII: S1542-3565(09)00451-0

doi:10.1016/j.cgh.2009.05.012

Refers to article:

  • PodcastLinking Article with Gastroenterology Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis , 27 January 2009

    Corey A. Siegel, Sadie M. Marden, Sarah M. Persing, Robin J. Larson, Bruce E. Sands
    Clinical Gastroenterology and Hepatology August 2009 (Vol. 7, Issue 8, Pages 874-881)

Clinical Gastroenterology and Hepatology
Volume 7, Issue 10 , Page 1139, October 2009